Lin Ziwei, Zhu Hao, Si Si, Xu Jiawei, Artime Esther, Khare Swarna, Higgins Victoria, Leith Andrea, Bi Yan
Eli Lilly and Company, Suzhou, China.
Eli Lilly and Company, Alcobendas, Spain.
Endocrine. 2025 Jul 1. doi: 10.1007/s12020-025-04315-7.
To describe management and barriers regarding weight loss in China.
Data were from the Adelphi Real World Obesity Disease Specific Programme™, a cross-sectional survey between April and July 2022 in Chinese clinical practice. Physicians managing people with obesity or overweight (PwO) and PwO aged ≥ 18 years, under weight management programs, and/or with a body mass index ≥ 28 kg/m were eligible.
100 physicians and 801 PwO were included. Before current clinical management, PwO had attempted self-management using their own diet (87%) and exercise (84%) programs, natural remedies/diet pills sold on the internet (26%) or over the counter diet pills (19%). Physicians reported that typical first-line weight management methods in clinical practice were diet (82%) and exercise (82%), with half (50%) using drug approaches. Only 19% of PwO reported full compliance with diet and exercise programs. Among the 78 physicians who used anti-obesity medications (AOMs), the single most important reason for initiating AOM was failure to reach the desired weight loss with diet and exercise alone (58%). Of the 78 physicians, 67% felt that most weight loss approaches always fail and 73% felt that AOM options were restricted; the top rated single most desired improvements in future AOMs were improved or greater efficacy (26%) and safer long-term use (26%). Of PwO, most (88%) had some willingness to try a new AOM.
PwO usually self-managed initial weight loss attempts. Physicians typically initiated lifestyle interventions as first-line treatment despite low PwO compliance. Both physicians and PwO desired improved AOMs. Of note, no approved prescription-only AOMs were available in China during the time window of the study.
描述中国体重减轻的管理情况及障碍。
数据来自阿德尔菲真实世界肥胖疾病特定项目™，这是一项于2022年4月至7月在中国临床实践中开展的横断面调查。管理肥胖或超重患者（PwO）的医生以及年龄≥18岁、处于体重管理项目之下和/或体重指数≥28 kg/m²的PwO符合条件。
纳入了100名医生和801名PwO。在当前临床管理之前，PwO曾尝试通过自行制定的饮食（87%）和运动（84%）计划、互联网上售卖的天然疗法/减肥药（26%）或非处方减肥药（19%）进行自我管理。医生报告称，临床实践中典型的一线体重管理方法是饮食（82%）和运动（82%），半数（50%）会使用药物方法。只有19%的PwO报告完全遵守饮食和运动计划。在使用抗肥胖药物（AOM）的78名医生中，开始使用AOM的最重要单一原因是仅通过饮食和运动未能达到期望的体重减轻效果（58%）。在这78名医生中，67%认为大多数体重减轻方法总是失败，73%认为AOM的选择受限；未来AOM最期望的单一改进是疗效提高或更好（26%）以及长期使用更安全（26%）。在PwO中，大多数（88%）愿意尝试新的AOM。
PwO通常会自行管理最初的体重减轻尝试。尽管PwO的依从性较低，但医生通常将生活方式干预作为一线治疗方法。医生和PwO都期望改进AOM。值得注意的是，在研究的时间范围内，中国没有获批的仅用于处方的AOM。
